Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir

Pharmacology

Volumn 82, Issue 4, 2008, Pages 287-292

  Donnerer, Josef ^a   Haas, Bernhard J ^b   Kessler, Harald H ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

Antiretroviral medication; Human immunodeficiency virus; Therapeutic drug monitoring, single measurement

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; PLASMA HALF LIFE; PRIORITY JOURNAL;

ADULT; AGED; ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 53849120594     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000164222     Document Type: Article

References (27)

1. Haas DW: Can responses to antiretroviral therapy be improved by therapeutic drug monitoring? Clin Infect Dis 2006;42:1197-1199.
2. Back DJ, Khoo SH, Gibbons SE, Merry C: The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol 2001;51:301-308.
3. Mallon PW, Ray J, Cooper DA: Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. J Clin Virol 2003;26:223-227.
4. Crommentuyn KM, Kappelhoff BS, Mulder JW, Mairuhu AT, van Gorp EC, Meenhorst PL, Huitema AD, Beijnen JH: Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005;60:378-389.
5. Wateba MI, Billaud E, Dailly E, Jolliet P, Raffi F: Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients. HIV Med 2006;7:197-199.
6. Moltó J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, Delavarga M, Fumaz CR, Barbanoj MJ, Clotet B: Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol 2007;63:715-721.
7. Back DJ, Blashke T, Boucher C, Burger D, Fletcher C, Flexner C, Gerber J, Schapiro J: Optimizing TDM in HIV clinical care: a practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents 2006. http://www.hivpharmacology.com (accessed February 18, 2008).
8. Takahashi M, Ibe S, Kudaka Y, Okumura N, Hirano A, Suzuki T, Mamiya N, Hamaguchi M, Kaneda T: No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART. AIDS Res Hum Retroviruses 2007;23:983-987.
9. Kewn S, Maher B, Hoggard P, Khoo S, Carey P, Wilkins E, Gould J, Back DJ: The pharmacokinetics of abacavir phosphorylation in peripheral blood mononuclear cells from HIV positive subjects. AIDS 2000;14:S95.
10. McDowell JA, Lou Y, Symonds WS, Stein DS: Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000;44:2061-2067.
11. Stein DS, Moore KH: Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 2001;21:11-34.
12. Kakuda TN, Page LM, Anderson PL, Henry K, Schacker TW, Rhame FS, Acosta EP, Brundage RC, Fletcher CV: Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob Agents Chemother 2001;45:236-242.
13. Panhard X, Legrand M, Taburet AM, Diquet B, Goujard C, Mentré F, the Cophar 1 - ANRS 102 Study Group: Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. Eur J Clin Pharmacol 2007;63:1019-1029.
14. Donnerer J, Kronawetter M, Kapper A, Haas I, Kessler HH: Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. Pharmacology 2003;69:197-204.
15. Moyer TP, Temesgen Z, Enger R, Estes L, Charlson J, Oliver L, Wright A: Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem 1999;45:1465-1476.
16. Weller S, Radomski KM, Lou Y, Stein DS: Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2000;44:2052-2060.
17. Verweij-van Wissen CP, Aarnoutse RE, Burger DM: Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J Chromatogr B Anal Technol Biomed Life Sci 2005;816:121-129.
18. Best BM, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, Read JS, Smith E, Hu C, Spector SA, Connor JD, PACTG P1026s Study Team: Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006;20:553-560.
19. Marier JF, Borges M, Plante G, Dimarco M, Morelli G, Tippabhotla SK, Vijan T, Singla AK, Garg M, Monif T: Bioequivalence of abacavir generic and innovator formulations under fasting and fed conditions. Int J Clin Pharmacol Ther 2006;44:284-291.
20. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004;18:2391-2400.
21. Rodriguez-Novoa S, Barreiro P, Rendón A, Jiménez-Nacher I, González-Lahoz J, Soriano V: Influence of 516G → T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005;40:1358-1361.
22. Veldkamp AI, Van Heeswijk RP, Mulder JW, Meenhorst PL, Hoetelmans RM, Lange JM, Beijnen JH: Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine. Ther Drug Monit 2001;23:606-611.
23. Cooper CL, van Heeswijk RP: Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Med 2007;8:1-7.
24. Gonzalez-de-Requena D, Nunez M, Jimenez-Nacher I, Soriano V: Liver toxicity caused by nevirapine. AIDS 2002;16:290-291.
25. Ray J, Pang E, Carey D: Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography. J Chromatogr B 2002;775:225-230.
26. Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B: Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002;3:27-35.
27. Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S: Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrob Agents Chemother 2006;50:2079-2086.